MedPath

Association Between Pococyturia and Pre-eclampsia Severity

Recruiting
Conditions
Pre-Eclampsia
Interventions
Other: Dosage of urinary podocyturia
Registration Number
NCT03316391
Lead Sponsor
Hospices Civils de Lyon
Brief Summary

Pre-eclampsia is an hypertensive disorder appearing during pregnancy, inducing serious maternal, fetal and neonatal mortality and morbidity. Twenty four hours proteinuria is a key element to define pre-eclampsia severity but is delaying the result by 24 hours and constraining for the patient. A simple and rapid indicator for severe preeclampsia would help clinicians to make appropriate decision in patient management. We hypothesized that urinary podocyturia is correlated to preeclampsia severity. This is a prospective, non-interventional, monocentric study.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
30
Inclusion Criteria
  • women aged 18 years or more
  • single pregnancy
  • admission for pre-eclampsia
  • patient receiving information and non-opposition to participate
Read More
Exclusion Criteria
  • multiple pregnancy
  • in utero fetal demise excepted if associated with pre-eclampsia
  • antecedent of nephropathy
  • fetal malformation, chromosomal anomalies
  • inability to understand information provided
  • prisoner or under administrative supervision
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Pre-eclampsiaDosage of urinary podocyturiaPatients in hospital for pre-eclampsia at the Hopital Femme-Mère-Enfant
Primary Outcome Measures
NameTimeMethod
Severity of pre-eclampsiaat childbirth (maximum 10 months)

Severe preeclampsia is defined by preeclampsia with at least one of the following criteria :

* severe hypertension (PAS ≥ 160 mmHg et/ou PAD ≥ 110 mmHg)

* Renal impairment with: oliguria \<500 ml / 24h or creatinine\> 135 μmol / L or proteinuria\> 5 g/d

* acute lung edema or persistent epigastric bar or HELLP syndrome

* eclampsia or rebellious neurological disorders (visual disturbances, polykinetic ROT, headache),

* thrombocytopenia \<100 G / L

* Retro Placental Hematoma (HRP) or fetal repercussion.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Service de gynécologie-obstétrique

🇫🇷

Pierre-Bénite, Rhône, France

Department of obstetrics, Femme Mère Enfant Hospital, Lyon, France

🇫🇷

Bron, France

© Copyright 2025. All Rights Reserved by MedPath